Partida Ramon A, Yeh Robert W
Division of Cardiology, Department of Medicine, Massachusetts General Hospital, 55 Fruit Street, GRB-800 Boston, MA 02114, USA; Institute for Medical Engineering and Science, Massachusetts Institute of Technology, 77 Massachusetts Avenue, E25-438, Cambridge, MA 02139, USA; Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA.
Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA; Department of Medicine, Smith Center for Outcomes Research in Cardiology, CardioVascular Institute, Beth Israel Medical Center, 330 Brookline Avenue, Baker 4, Boston, MA 02215, USA; Harvard Clinical Research Institute, Boston, MA, USA.
Cardiol Clin. 2017 May;35(2):281-296. doi: 10.1016/j.ccl.2016.12.010.
First-generation drug-eluting stents significantly improved treatment of coronary disease, decreasing rates of revascularization. This was offset by high rates of late adverse events, driven primarily by stent thrombosis. Research and design improvements of individual DES platform components led to next-generation devices with superior clinical safety and efficacy profiles compared with bare-metal stents and first-generation drug-eluting stents. These design improvements and features are explored, and their resulting clinical safety and efficacy reviewed, focusing on platforms approved by the Food and Drug Administration currently widely used in the United States.
第一代药物洗脱支架显著改善了冠心病的治疗，降低了血运重建率。但这被主要由支架血栓形成导致的高晚期不良事件发生率所抵消。对单个药物洗脱支架平台组件的研究和设计改进催生了下一代装置，与裸金属支架和第一代药物洗脱支架相比，其具有更优异的临床安全性和有效性。本文探讨了这些设计改进和特性，并对由此产生的临床安全性和有效性进行了回顾，重点关注目前在美国广泛使用的、已获美国食品药品监督管理局批准的平台。
